Atlas Trials

Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

Clinical trial NCT04109482 · TERMINATED

Trial details

NCT number
NCT04109482
Sponsor
Mustang Bio
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Start date
2020-02-17
Primary completion
2023-05-17
Enrollment
3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.